PT - JOURNAL ARTICLE AU - Tamer Oraby AU - Michael G Tyshenko AU - Jose Campo Maldonado AU - Kristina Vatcheva AU - Susie Elsaadany AU - Walid Q Alali AU - Joseph C Longenecker AU - Mustafa Al-Zoughool TI - Modeling the Effect of Lockdown Timing as a COVID-19 Control Measure in Countries with Differing Social Contacts AID - 10.1101/2020.11.14.20231886 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.14.20231886 4099 - http://medrxiv.org/content/early/2020/11/16/2020.11.14.20231886.short 4100 - http://medrxiv.org/content/early/2020/11/16/2020.11.14.20231886.full AB - The application, timing, and duration of lockdown strategies during a pandemic remain poorly quantified with regards to expected public health outcomes. Previous projection models have reached conflicting conclusions about the effect of complete lockdowns on COVID-19 outcomes. We developed a stochastic continuous-time Markov chain (CTMC) model with eight states including the environment (SEAMHQRD-V), and derived a formula for the basic reproduction number, R0, for that model. Applying the R0 formula as a function in previously-published social contact matrices from 152 countries, we produced the distribution and four categories of possible R0 for the 152 countries and chose one country from each quarter as a representative for four social contact categories (Canada, China, Mexico, and Niger). The model was then used to predict the effects of lockdown timing in those four categories through the representative countries. The analysis for the effect of a lockdown was performed without the influence of the other control measures, like social distancing and mask wearing, to quantify its absolute effect. Hypothetical lockdown timing was shown to be the critical parameter in ameliorating pandemic peak incidence. More importantly, we found that well-timed lockdowns can split the peak of hospitalizations into two smaller distant peaks while extending the overall pandemic duration. The timing of lockdowns reveals that a “tunneling” effect on incidence can be achieved to bypass the peak and prevent pandemic caseloads from exceeding hospital capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.A. received Grant number CORONA PROP 46 from the Kuwait Foundation for the Advancement of Sciences (KFAS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A